Aethlon, Commonwealth sign cooperative research agreement seeking grants for Hemopurifier

By E. Janene Geiss

Philadelphia, March 29 - Aethlon Medical, Inc. said Wednesday that it has signed a cooperative research agreement with Commonwealth Biotechnologies, Inc.

Under the agreement, Aethlon and Commonwealth will collaborate to pursue federal grant and research opportunities for the Aethlon Hemopurifier within biodefense and pandemic preparedness programs, according to a company news release.

Since 1999, Commonwealth researchers have managed or participated in awarded biodefense grants exceeding $20 million, officials said. Commonwealth also operates a secure BSL-3 containment facility able to receive and work with select agents as defined by the Centers for Disease Control.

"In addition to its obvious value as a treatment for acute viral infections, the Hemopurifier technology developed by Aethlon has enormous potential as a device to manage exposure to the viral agents identified by the CDC and other agencies as biothreat agents," Richard J. Freer, chairman and chief operating officer of Commonwealth, said in the release.

The Hemopurifier is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 avian flu and chronic infectious disease targets including hepatitis C and HIV.

Aethlon said it has begun research on a second generation Hemopurifier that targets the capture of growth factors inherent in the spread of cancer.

Aethlon, based in San Diego, is the developer of the Hemopurifier.

Commonwealth is a Richmond, Va., solutions provider to the global biotechnology industry, academic institutions, government agencies and pharmaceutical companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.